





BIR ANNUAL RADIOTHERAPY AND ONCOLOGY DEETING 2023 30 March-31 March 2023 etc.venues St Paul's, London



12 CPD credits (6 credits per day)

BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2023

This is the third meeting for the BIR, which brings together speakers from around the world and national experts too, to share experiences and expertise in a wide range of aspects for today's cutting-edge radiotherapy and oncology. As with 2022's highly successful face-to-face meeting, this one will include presentation and discussion of the latest techniques, technologies, methods and hot-topics in radiotherapy and oncology....do come and join us! Renewed opportunities aplenty for networking with fellow professionals and discussing the latest offerings from manufacturers; and presenting your own material too.

As previously, parallel streams will be used to maximise the sessional opportunities, together with expert plenary talks on "Patient voices" and other state-of-the-art topics in radiotherapy.

Schedule of event

Day one

09:00 Registration opens 09:20 Welcome speech 09:30 Lecture begins 13:00 Lunch and networking 17:00 Close of day

Day two

09:00 Registration opens 09:30 Lecture begins 13:00 Lunch and networking 14:00 BIR Medal for Outstanding International Achievement 17:00 Close of day

Who should attend?

This event will appeal to anyone working within radiotherapy and oncology including clinical oncologists, radiographers, physicists, service managers, Linac and IT engineers, dosimetrists, manufacturers and department heads.

Five reasons to attend

- 1. Enhance your knowledge
- 2. Hear expert opinion and share your own
- 3. Refresh your understanding
- 4. Share your own research
- 5. Network with colleagues, peers and industry representatives

BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2023

ePosters

There will be electronic posters in an online format, which can be viewed anytime from a computer, laptop or mobile device.



Headline sessions

Day one Plenary lecture on Patient voices

Day two Plenary lecture BIR Medal for Outstanding International Achievement

Professor Søren Bentzen Director of the Division of Biostatistics and Bioinformatics, University of Maryland, and Director of the Biostatistics Shared Service, University of Maryland Greenebaum Cancer Center



BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2023 WELCOMES ITS INDUSTRY PARTNERS

Platinum Sponsors



Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology. We are committed to transforming patients' lives by leading innovation in nuclear medicine. AAA currently has over 1,000 employees working across 31 sites in 12 countries (Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US). The company also has global manufacturing capabilities with 19 facilities in eight countries, and six research & development sites. For more information, please visit: https://www.adacap.com/



Bayer's Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999 www. radiology.bayer.co.uk



GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.



Siemens Healthineers is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care to patients. For more information and latest product line visit www.siemenshealthineers.co.uk

PHILIPS

Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people's lives across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people's health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. www.philips.co.uk/healthcare

Thank you to our sponsors! **Premium MVISION** RAD formation - Al for Precision Radiotherapy -🕑 Elekta variar A Siemens Healthineers Company OS Silver THE DOS Bronze RaySearch Laboratories **Oncology Imaging Systems** Vertec . E R T U A L

Thursday 30 March

Stream A	
09:00	Registration and refreshments
09:20	Welcome and introduction

Session 1: MR informed radiotherapy

Chair: Mr Scott Hanvey	
09:30	Commissioning an MR sim and overview of IPEM guidance on the use of MRI for external beam radiotherapy Dr Richard Speight, Principal Clinical Scientist, Leeds Teaching Hospitals NHS Trust
10:00	MRI-Linac: Technical concepts Professor Gary Liney, MRI-Linac Lead Physicist, Independent MRI-RT physicist
10:30	Inter-observer variability of contours for locally advanced pancreatic cancer on the MR Linac Jessica Gough, Clinical Research Fellow, The Royal Marsden NHS Foundation Trust
10:45	Using immobilisation masks in magnetic resonance imaging radiotherapy planning scans: The experiences of male patients with head and neck cancers Louise Jordan, Research Radiographer, Newcastle Hospitals NHS Foundation Trust

11:00 Break

Session 2: Adaptive radiotherapy

Chair: Mr Alex Morris	
11:30	Integrating MR-guided adaptive SABR into modern oncology practice Dr James Good, Consultant Clinical Oncologist, University Hospitals Birmingham NHS Foundation Trust
12:00	Adaptive proton therapy: Making radiosurgery the new norm? Professor Tony Lomax, Chief Medical Physicist, Paul Scherrer Institute
12:30	Early experiences of implementing therapeutic radiographer target volume contouring for magnetic resonance image guided adaptive radiotherapy Ms Bethany Williams, Senior 1 MR Linac Therapeutic Radiographer, The Royal Marsden NHS Foundation Trust

13:00 Lunch

	Plenary session: Patient voices
	Chair: Ms Sarah-Jane Ketterer
14:00	Title to be confirmed
	Ms Jemima Reynolds, Head of Programmes and Engagement, Trekstock
14:20	Patient prostate cancer options website
	Dr Diane Whitney, Head of Brachytherapy Physics, Cambridge University Hospitals NHS Foundation Trust
14:40	A patient's voice in research: Introduction to patient and public involvement (PPI)
	Mr Andrew Wragg, Patient and Public Involvement Manager (Research and Innovation), Nottingham University
	Hospitals NHS Trust

15:00 Break

Session 3: Manufacturer session

Chair: Mr Phil Neale	
15:30	Introducing Hypersight™ Mr Michael Stead, Senior Product Marketing Manager, Varian
15:45	Enhancing accuracy and efficiency in dosimetry data collection with SunSCAN 3D Mr Greg Martin, Application Scientist, Sun Nuclear - A Mirion medical technologies company
16:00	Title to be confirmed Dr Karl Otto, CEO, Limbus AI (for AMG Medtech)
16:15	Evaluation of myQA® SRS Detector as a tool for stereotactic body radiotherapy plan quality assurance Ms Sally Fletcher, Head of Radiotherapy Physics, Bristol Haematology and Oncology Centre (for Oncology Systems Limited)
16:30	How to standardise radiotherapy Mr Jarkko Niemelä, Chief Product Officer, Co-Founder, MVision
16:45	Optimizing radiation oncology workflows with automation Mr Mauricio Leick, Medical Physicist, Team Leader for Radiation Planning at the KSA-KSB Radio-Oncology Center, Kantonsspital Aarau AG (Switzerland) (for Radformation)
17:00	Advanced imaging and interoperability in radiation oncology Dr Sylvain Reuzé, Clinical Applications Leader Radiotherapy, GE Healthcare

17:15 Close of day

Thursday 30 March

Strean	n B
09:00	Registration and refreshments
09:20	Welcome and introduction

Session 1: Making radiotherapy more effective

Chair: Mrs Nicola Blackler and Mr Charles Kelly

09:30	Practical implementation of BIR guidance for margin determination: Experience, tips and learning Dr Isabel Palmer, Principal Radiotherapy Physicicst (Imaging Lead), Barts Health NHS Trust
10:00	Single-dose ablative radiation therapy for prostate cancer with target motion mitigation Dr Valeria Faccenda, Medical Physicist, Fondazione IRCCS San Gerardo dei Tintori, Monza (Italy)
10:30	Radiotherapy for breast cancer: How clinical trials have changed practice Dr Anna Kirby, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust and President, European Society Radiation Oncology

11:00 Break

Session 2: SRS/SABR

Chair: Mrs Nicola Blackler	
11:30	Practical considerations of single fraction lung SABR Dr Clive Peedell, Consultant Clinical Oncologist, South Tees NHS Foundation Trust
12:00	Launch of the RCR / UK SABR consortium national audit of SABR reirradiation in the pelvis Dr Rebecca Muirhead, Clinical Oncologist, Oxford University Hospital NHS Foundation Trust
12:30	A novel phantom and workflow for SIMT-SRS QA: Cost-effective 3D dose error measurement Mr Jonathan Lane, Head of Radiotherapy Physics, Oxford University Hospitals NHS Foundation Trust

13:00 Lunch

	Plenary session: Patient voices
	Chair: Ms Sarah-Jane Ketterer
14:00	To be forewarned is to be forearmed. What I wish I'd known about radiotherapy from a young adult's perspective
	Jemima Reynolds, Head of Programmes and Engagement, Trekstock
14:20	Patient prostate cancer options website
	Dr Diane Whitney, Head of Brachytherapy Physics, Cambridge University Hospitals NHS Foundation Trust
14:40	A patient's voice in research: Introduction to patient and public involvement (PPI)
	Andrew Wragg, Patient and Public Involvement Manager (Research and Innovation), Nottingham University Hospitals NHS Trust
15:00	Break

Session 3: Resources and sustainability

Chair: Dr Mike Kirby

15:30	Sustainability in brachytherapy and nuclear medicine related to radiotherapy Dr Nathan Dickinson, Nottingham University Hospitals NHS Trust; Dr Gerry Lowe, Principal Clinical Scientist, Mount Vernon Cancer Centre
16:00	Addressing environmental sustainability: The answer to workforce in radiotherapy and oncology? Mr Ross McGhee, President, Society and College of Radiographers and Radiotherapy Board Member
16:30	Do more with less: How to assess value in radiation oncology Dr Ajay Aggarwal, Consultant Clinical Oncologist, Guy's and St Thomas' NHS Foundation Trust

Friday 31 March

Stream A 09:00 **Registration and refreshments** Session 1: Brachytherapy **Chair: Dr Keith Langmack** 09:30 Development of the prostate brachytherapy service at the Norfolk and Norwich Hospital Mr Sam Worster, Consultant Radiographer, Norfolk and Norwich University Hospitals NHS Foundation Trust 09:50 HDR Skin brachytherapy service development Dr Amarnath Challapalli, Clinical Director and Consultant Clinical Oncologist, Bristol Hematology and Oncology Center, University Hospitals Bristol and Weston NHS Foundation Trust 10:10 What's the role of prostate brachytherapy in the modern world? Professor Gerard Morton, Radiation Oncologist, Sunnybrook Health Sciences Centre and Associate Professor, Department of Radiation Oncology, University of Toronto, Canada

10:30 **Modern tools for brachytherapy: From image guidance to model based dose calculation** Professor Tomas Kron, Director of Physical Sciences, Peter MacCallum Cancer Centre

11:00 Break

Session 2: IGRT/SGRT

Chair: Ms Amanda Webster11:30Radiotherapy imaging dose and optimisation, and the importance of collaborative working
Dr Tim Wood, Principal Medical Physicist, Radiation Protection Adviser, Medical Physics Expert, Radiation
Protection and Radiology Physics, Hull University Teaching Hospitals NHS Trust12:00Quality assurance on surface-guided radiotherapy – current status and perspectives
Dr Vania Batista, Medical Physicist, Heidelberg University Hospital, Germany12:30Evaluating the setup and immobilisation accuracy of faceless masks using SGRT/IGRT
Dr Mark Ramtohul, Principal Clinical Scientist, University Hospitals Birmingham NHS Foundation Trust

13:00 Lunch

14:00	Plenary session Radiation oncology in the era of data science: BIR Medal for Outstanding International Achievement Professor Søren Bentzen, Director of the Division of Biostatistics and Bioinformatics, University of Maryland, and Director of the Biostatistics Shared Service, University of Maryland Greenebaum Cancer Center

Session 3: Safety and regulations

Chair: Mr Alex Morris		
15:30	Accidental or unintended exposures – an expansion of the simple risk assessment to promote real safety management in radiotherapy Mrs Oonagh Maguire and Mrs Una McElroy, Quality Assurance Radiographer, Northern Ireland Cancer Centre – Radiotherapy Department Belfast City Hospital Belfast Health and Social Care Trust	
16:00	In-house manufacture in radiotherapy: New Medical Device Regulation requirements Mr David Grainger, Technical Lead Software, AI and MRI, Devices Division, Medicines and Healthcare products Regulatory Agency	
16:30	The Ionising Radiations Regulations 2017: The new consent process Mr James Taylor, Principal Specialist Inspector (Radiation), Health and Safety Executive Radiation Team	

Friday 31 March

Stream B		
09:00	Registration and refreshments	
Session 1: Particle therapy		
Ms Samaneh Shoraka and Mr Andrew Poynter		
09:30	An update on proton beam therapy in the UK Dr Colin Baker, Group Lead for Proton Beam Therapy Physics, University College London Hospitals NHS Foundation Trust	
10:00	The LIGHT proton therapy system: Development and UK projects Dr Jonathan Farr, Chief Clinical Officer, Advanced Oncotherapy plc	
10:30	Proton therapy research in Manchester Professor Karen Kirkby, Professor of Proton Therapy Physics, University of Manchester	

11:00 Break

Session 2: Individualised radiotherapy (including Immunotherapy)

Chair: Ms Nicola Blackler

11:30	Artificial intelligence with radiomics Dr Helen Wang, Trainee in Medical Physics, The Royal Surrey County Hospital NHS Foundation Trust
12:00	Intensity modulated total body irradiation using TomoDirect™ Dr Andrew Dumbill, Clinical Scientist, University Hospitals Birmingham NHS Foundation Trust
12:15	Dosimetric impact of intrafraction prostate motion and interfraction anatomical changes in dose-escalated linac-based SBRT Dr Valeria Faccenda, Medical Physicist, Fondazione IRCCS San Gerardo dei Tintori, Monza (Italy)
12:30	Dose painting radiotherapy for prostate cancer: A better option for patients with localised high risk disease? Professor Isabel Syndikus, Consultant in Clinical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust

13:00 Lunch

14:00 Plenary session Radiation oncology in the era of data science: BIR Medal for Outstanding International Achievement Professor Søren Bentzen, Director of the Division of Biostatistics and Bioinformatics, University of Maryland, and Director of the Biostatistics Shared Service, University of Maryland Greenebaum Cancer Center

15:00 Break

Session 3: Big data and cybersecurity / AI associated regulations

Chair: Dr Keith Langmack		
15:30	Real-world data on comorbidity and radiotherapy-induced toxicity in cancer patients Dr Azadeh Abravan, Research Associate, The University of Manchester	
16:00	Experience of a national Cyberattack: A Medical Physicists perspective Dr Brendan McClean, Director of Physics, Saint Luke's Radiation Oncology Network	
16:30	Experience of a national Cyberattack: A Radiation Oncologists perspective Dr Aileen Flavin, Consultant Radiation Oncologist, Bon Secours/UMPC Radiotherapy Centre in Cork	



Thank you to our Platinum sponsors!



🈏 @BIR_News



in The British Institute of Radiology



Audrey House, 16-20 Ely Place, London EC1N 6SN www.bir.org.uk

Registered charity number: 215869